Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by garygpon Aug 16, 2023 11:56am
173 Views
Post# 35591096

Happiness.

Happiness.I'm overjoyed and happy beyond belief to know we are partnered with the likes of the FSG bunch who are going to see us through these tough times and secure a place for PMN at the table with big pharma.

What a freeking joke. So the low of 2.10 today still isn't low enough for these slobs to do a financing.  What's it going to take; a low of 3 cents before they are ready to do a financing? 

We should all be thinking of the saying, "Be careful what you wish for."  By the time the financing  is done the words of the WEF and Klaus Schwab will be echoing though the PMN halls......"You will own nothing, and be happy".

This whole story since the FSG bunch has become involved stinks to high heaven.   There is little doubt that by the time this story plays out, we are going to have our heads handed to us on a platter.   g
<< Previous
Bullboard Posts
Next >>